Search
glofitamab-gxbm (Columvi)
Indications:
- diffuse large B-cell lymphoma*
* improves overall survival over rituximab [2]
Dosage:
- pretreatment with 1 g intravenous obinutuzumab 7 days priot to the 1st dose of glofitamab
- cycle 1: day 8: 2.5 mg glofitamab IV; day 15: 10 mg IV
- cycle 2-12: 30 mg on day 1
- cycles lasted 21 days
* 1 mg/mL
Adverse effects:
- >= grade 3: 62%
- cytokine release syndrome
- gastrointestinal hemorrhage
- neutropenia
- sepsis
- delirium
Mechanism of action:
- CD20-CD3 bispecific monoclonal antiboduy
- 2:1 tumor:T-cell binding configuration
- bivalent for CD20 (B-cells) & monovalent for CD3 (T-cells)
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Dickinson MJ, Carlo-Stella C, Morschhauser F et al.
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2022 Dec 15;387(24):2220-2231.
PMID: 36507690 Clinical Trial
https://www.nejm.org/doi/full/10.1056/NEJMoa2206913
- Bassett M
Glofitamab Regimen Improves Survival in DLBCL.
Granted accelerated approval last year, bispecific antibody passes its
confirmatory test.
MedPage Today June 20, 2024
https://www.medpagetoday.com/meetingcoverage/eha/110740